Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Escamilla Gomez, Virginia

Oral and Poster Abstracts
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II

adult, Research, Clinical Practice (Health Services and Quality), Clinical Research, pediatric, real-world evidence, Human, Study Population

Virginia Escamilla Gomez^1,2^*, Valentín García Gutiérrez, PhD³, Beatriz Astibia Mahillo, MD⁴^*, Patricia Alcalde, MD⁵^*, Lucía López Corral, MD PhD⁶^*, Marina Acera Gómez, Data Manager⁷^*, Melissa Torres, MD⁸^*, Asunción Borrego Borrego, MD⁸^*, Leslie González Pinedo, MD⁸^*, Maite Zudaire, MD⁹^*, Marta González Vicent, MD¹⁰^*, Ana Benzaquén, MD¹¹^*, Isabel Izquierdo Garcia¹²^*, Pedro Asensi¹³^*, Juan Montoro Gómez, MD¹⁴^*, Guillermo Orti Pascual, MD¹⁵^*, David Valcárcel, MD, PhD¹⁶, Maria Isabel Benitez Carabante, MD¹⁷^*, Cristina Díaz de Heredia Rubio, MD¹⁸^*, Eloi Cañamero Giro, MD¹⁹^*, Christelle Ferrà, MD²⁰^*, Irene García-Cadenas, MD²¹^*, Sara Redondo, MD²¹^*, Luisa Sisinni, MD²²^*, Antonio Perez, MD, PhD²³^*, Alberto Mussetti²⁴^*, Lucía García, MD²⁵^*, María Del Pilar Palomo Moraleda, MD²⁶^*, Pedro Antonio González Sierra, Physician²⁷^*, Manuel Jurado Chacón, MD²⁸^* and Jose A. Perez-Simon, MD, PhD²⁹

¹Department of Hematology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
²Department of Hematology, Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain
³Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain
⁴Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
⁵Hematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
⁶Department of Hematology, Hospital Clínico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain
⁷Hematology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
⁸Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
⁹Hematology Department, Hospital Universitario de Navarra, Pamplona, Spain
¹⁰Hematopoietic Transplant Department, Hospital Universitario Niño Jesús, Madrid, Spain
¹¹Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Valencia, Spain
¹²Hematology Department, Hospital Universitario Miguel Servet, Zaragoza, ESP
¹³Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
¹⁴Hematology Department, Hospital Universitario y Politécnico la Fe, Valencia, Spain
¹⁵Hematology Department, Hospital Universitario Vall d´Hebron, Barcelona, Spain
¹⁶Department of Hematology, University Hospital Vall d’Hebron, Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), University Autonoma of Barcelona (UAB), Barcelona, Spain
¹⁷Hematology and Oncology Department, Hospital Universitario Vall d´Hebron, Barcelona, Spain
¹⁸Division of Pediatric Hematology and Oncology, Hospital Universitario Vall d´Hebron, Barcelona, Spain
¹⁹Hematology Deparment, Hospital Universitario Germans Trias i Pujol - Institut Català d'Oncologia, Barcelona, Spain
²⁰Hematology Department, Hospital Universitario Germans Trias i Pujol - Institut Català d'Oncologia, Barcelona, Spain
²¹Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
²²Hemato-Oncology Pediatric Service, Hospital Universitario La Paz, Madrid, ESP
²³Hemato-Oncology Pediatric Service, Hospital Universitario La Paz, Madrid, Spain
²⁴Department of Hematology, Hospital Duran i Reynals, Instituto Catalán de Oncología, L'Hospitalet De Llobregat, Barcelona, Spain
²⁵Hospital Universitario Son Espases, Islas Baleares, Spain
²⁶Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
²⁷Department of Hematology, Complejo Hospitalario Universitario de Granada, Granada, Spain
²⁸Hematology Department, Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain
²⁹Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IBIS / CSIC), Universidad de Sevilla, Sevilla, Spain

Introduction

The JAK1/2 inhibitor ruxolitinib has been approved for the treatment of adults and paediatric patient ≥12 years with steroid refractory graft-versus-host disease (GvHD) based on the REACH-2 and 3 studies. However, real-life studies are needed to validate the results of clinical trials and assess its efficacy in specific organs, particular population groups such as paediatric patients, and possibility to reduce immunosuppression. Moreover, these pivotal studies focused on ruxolitinib after failure to corticosteroids and showed no data about its efficacy after more than one previous line of treatment.

Methods

A descriptive, retrospective, multi-centre study of adult and paediatric patients (<14 years) treated with ruxolitinib for steroid-refractory acute or chronic GvHD from 16 Spanish hospitals belonging to the Spanish Transplantation Group (GETH) between October 2015 and June 2022. The severity of GvHD was evaluated according to the Glucksberg/Magic/Harris criteria for acute GvHD and according to the international consensus of National Institutes of Health (NIH) for chronic GvHD.

Results

A total of 366 patients were analysed: 324 adults and 42 paediatric patients. Their baseline characteristics and response and toxicity data are described in Tables 1 and 2.

Adult patient group. In acute GvHD, overall response (OR) was observed in 57.6% of patients after a median of 2 weeks of treatment, and 30.7% achieved complete remission (CR). Dose of corticosteroids was reduced in 63.5% of patients. Cytopenias grades ≥3 were observed in 11.3% of patients. Infections included CMV replication (51%), fungal infection (19.2%) and herpes zoster (6.7%). Twelve patients relapsed of their underlying disease. Sixty-six patients died due to: GvHD 17 (25.7%), relapse 4 (6%), infection 36 (54.5%) and other 9 (13.6%). The median overall survival (OS) was 4.1 months, and at 2 years the OS was 28.8% (95%CI: 19.1-39.2). Median follow-up was 2.8 months (range: 0.1-71.6).

In chronic GvHD, the OR was 65.6% and was obtained after a median of 4 weeks of treatment; 18% achieved CR. OR in patients with scleroderma, gastrointestinal tract (GI) or lung involvement was 66.6%, 76% and 42%, respectively. The dose of corticosteroids was reduced in 68.3% and ruxolitinib was tapered in 37.9% of patients. Cytopenias grades ≥3 were observed in 5% of patients. Infections included CMV replication (14%), fungal infection (11.3%) and herpes zoster (5%). Seventeen patients relapsed of their underlying disease. Fifty-three patients died due to: GvHD 13 (24.5%), relapse 4 (7.5%), infection 23 (43.3%) and other 12 (22.6%). The median OS was not reached, and at 2 years the OS was 78.9% (95%CI: 72.5-84). Median follow-up was 26.8 months (range: 0.4-77).

Paediatric patients. In acute GvHD, 82.7% of patients with aGvHD responded after a median of 2 weeks of treatment and 51.7% achieved CR. Corticosteroids were reduced in 79.3% and ruxolitinib in 34.4% of patients. Cytopenias occurred in 3.4% of patients. Infections included CMV replication (34.5%), fungal infection (10.3%) and herpes zoster (17.2%). Four patients relapsed of their underlying disease. Eleven patients died due to: GvHD 3 (27.2%), relapse 2 (18.8%), infection 3 (27.2%) and other 3 (27.2%). The median OS was not reached, and at 2 years the OS was 59.2% (95%CI: 38.2-75.1). Median follow-up was 8.9 months (range: 0.4-59.5).

In chronic GvHD, OR was 100% after a median of 4 weeks of treatment and 23% achieved CR. Corticosteroids and ruxolitinib were reduced in 69.2% and 23% of patients, respectively. Cytopenias occurred in 7.7%. Infections included CMV replication (23.1%), fungal infection (15.4%) and herpes zoster (7.7%). Only 1 patient died due to relapse of the underlying disease; there were 2 relapses in total. The median OS was not reached, and at 2 years the OS was 100%. Median follow-up was 43.1 months (range: 0.9-59.6).

Conclusions

Ruxolitinib in the real world setting, showed similar results in terms of responses to clinical trials. In the paediatric population, the data are more favourable: Acute GvHD: 7%; chronic GvHD: 100%.
Results seems not be influenced by line of treatment (≥3).
By organ, main benetifs in cGvHD were seen in scleroderma (66.6%) and GI (76%) of the affected patients.
5% of adult patients and 79.3% of children with acute GVHD were able to reduce the dose of corticosteroids, while these figures were 68.3% and 69.2% for chronic GvHD.

Disclosures: Escamilla Gomez: Novartis: Research Funding. García Gutiérrez: Roche: Research Funding; BMS: Consultancy, Honoraria, Research Funding, Speakers Bureau; Incyte: Consultancy, Honoraria, Research Funding, Speakers Bureau; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Valcárcel: Astellas, Amgen, BMS/Celgene, Grifols, Jazz, Novartis, Sanofi, Sobi,: Consultancy, Honoraria, Speakers Bureau; Gebro, Janssen: Honoraria, Speakers Bureau. Mussetti: GILEAD: Research Funding; JAZZ PHARMACEUTICALS: Consultancy; BMS: Consultancy; TAKEDA: Honoraria. Perez-Simon: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, and Expenses; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, and Expenses; GILEAD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, and Expenses; JAZZ: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, and Expenses; ALEXION: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, and Expenses; ABBVIE: Research Funding; PFIZER: Research Funding.

See more of: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
See more of: Oral and Poster Abstracts

<< Previous Abstract | Next Abstract >>

^*signifies non-member of ASH

3451 Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study